Indeed, HER3 blockade with CDX-3379 promoted the regression of human HNSCC xenografts in immune deficient mice, but not in tumors that express activated PIK3CA mutants or in which aberrant pathway activation downstream of HER3 is sustained by PTEN deletion. Here, PIK3CA is linked to head and neck squamous cell carcinoma.